Voyager Therapeutics Reports Significant Revenue Decline and Increased Losses in Q3 2025

Voyager Therapeutics, Inc. reported a significant decline in financial performance for the third quarter of 2025, with collaboration revenue dropping to $13.4 million from $24.6 million in the same period last year. For the nine months ending September 30, 2025, total collaboration revenue was $25.0 million, down from $73.7 million in 2024. The decrease in revenue was primarily attributed to the absence of a $15 million amendment fee recognized in the previous year under the Novartis Option and License Agreement. The company continues to operate at a loss, reporting a net loss of $27.9 million for the third quarter and $92.3 million for the nine-month period, compared to losses of $9.0 million and $30.5 million, respectively, in the prior year.

Operating expenses increased to $44.0 million for the third quarter of 2025, up from $38.4 million in 2024, driven by higher research and development costs, which rose to $35.9 million from $30.2 million. The increase in R&D expenses was largely due to ongoing clinical trials, particularly for the VY7523 program, and costs associated with the Tau silencing gene therapy program. General and administrative expenses remained relatively stable, decreasing slightly to $8.1 million from $8.2 million, reflecting continued cost management following a reduction in workforce earlier in the year.

As of September 30, 2025, Voyager Therapeutics had total assets of $288.3 million, a decrease from $393.1 million at the end of 2024. The company's cash and cash equivalents stood at $45.1 million, down from $71.4 million, while marketable securities also decreased to $163.8 million from $195.3 million. The accumulated deficit increased to $418.5 million, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in its research and development pipeline.

In terms of strategic developments, Voyager Therapeutics has been focusing on its proprietary pipeline, which includes programs targeting neurological diseases such as Alzheimer’s and Parkinson’s. The company is advancing its VY7523 program, which is currently in a Phase 1 clinical trial, and has deprioritized investment in other programs to concentrate resources on its most promising candidates. Additionally, Voyager has entered into collaborations with Neurocrine and Novartis, which have provided substantial funding, although recent developments indicate a partial termination of the Novartis agreement affecting certain targets.

Looking ahead, Voyager Therapeutics expects to continue incurring significant expenses as it progresses its clinical trials and research initiatives. The company anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to meet its operational needs for at least the next twelve months. However, it acknowledges the need for additional funding to support its ongoing operations and development efforts, emphasizing the uncertainty surrounding future revenue generation from product sales or collaborations.